Nektar Therapeutics buy DerAlmanach100000
Start price
09.06.25
/
100%
€0.58
Target price
07.08.25
-
Performance (%)
-
End price
07.08.25
-
Summary
This prediction was cancelled by the user.Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Nektar Therapeutics | - | - |
| iShares Core DAX® | -1.212% | 1.925% |
| iShares Nasdaq 100 | -4.714% | -1.810% |
| iShares Nikkei 225® | -2.976% | -2.660% |
| iShares S&P 500 | -2.744% | -0.448% |
Comments by DerAlmanach100000 for this prediction
In the thread Trading Nektar Therapeutics
Die von DerAlmanach100000 gewählte maximale Laufzeit wurde überschritten